MAIA Biotechnology
MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a biotechnology company based in Chicago, Illinois, dedicated to the development of innovative therapies and immuno-oncology drugs aimed at treating various types of cancer. They focus particularly on targeting telomerase-positive cancer cells, representing a significant portion of human cancers that are often resistant to conventional treatments.
Products & Team
Ateganosine (THIO)
Ateganosine, also known as 6-thio-2'-deoxyguanosine (THIO), is MAIA's first-in-class investigational drug designed to target telomerase-positive cancer cells. It operates through a dual mechanism by disrupting telomeres to inhibit cancer cell growth and inducing immunogenic cell death to enhance the body's immune response against tumors.
THIO aims to provide effective treatment options for patients with advanced tumors that are unresponsive to existing therapies, thereby addressing a significant unmet medical need.
The need for more effective treatment options for cancers that do not respond to existing therapies, particularly for telomerase-positive cancer types.